{
    "clinical_study": {
        "@rank": "95930", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Holiday Group", 
                "arm_group_type": "Experimental", 
                "description": "Subjects in the Treatment Holiday Group will undergo a 6 month belimumab treatment holiday while remaining on standard of care SLE therapy, then re-start belimumab therapy for 6 months while receiving standard of care SLE therapy."
            }, 
            {
                "arm_group_label": "Control Group", 
                "arm_group_type": "Active Comparator", 
                "description": "Subjects in the Control Group will continue to receive monthly belimumab therapy, in addition to standard of care SLE therapy for 52 weeks."
            }, 
            {
                "arm_group_label": "Long-Term Discontinuation Group", 
                "arm_group_type": "No Intervention", 
                "description": "Subjects in the Long-Term Discontinuation Group have elected to discontinue further belimumab therapy and will remain on standard of care SLE therapy as directed by the investigator, and agree to return for monthly visits for 52 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the effect of a 24-week withdrawal followed by a 28-week\n      reintroduction of belimumab 10 mg/kg plus standard of care medications in subjects with\n      stable low systemic lupus erythematosus (SLE) disease activity.  Rebound phenomenon will be\n      assessed for subjects who have permanently withdrawn from further belimumab treatment."
        }, 
        "brief_title": "Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients.", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Systemic Lupus Erythematosus", 
        "condition_browse": {
            "mesh_term": "Lupus Erythematosus, Systemic"
        }, 
        "detailed_description": {
            "textblock": "This study will assess the effect of a 24-week withdrawal of belimumab followed by a 28-week\n      reintroduction of belimumab 10 mg/kg plus standard of care medications on immunogenicity,\n      markers of biological activity, efficacy, and safety in subjects with stable low systemic\n      lupus erythematosus (SLE) disease activity.  Additionally, this study will assess rebound\n      phenomenon in subjects with any disease level of SLE who have permanently withdrawn from\n      further belimumab treatment"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Received a minimun of 6 months therapy with with belimumab 10 mg/kg in their current\n             SLE belimumab continuation study.\n\n          -  Be 18 years of age at the Day 0 visit.\n\n          -  Non-prenant, non-lactating females willing to comply with specific birth control\n             requirements as set forth in the protocol.\n\n          -  Able to provide written informed consent to participate.\n\n          -  Subjects who wish to enroll in the control group and the group taking a 6 month\n             belimumab treatment holiday will need a SELENA SLEDAI score of 3 or less after the\n             minimum of 6 months belimumab therapy, as well as having C3 and C4 complement levels\n             at or above the lower limit of the central laboratory reference range, and are on a\n             stable SLE treatment regimen during the 30 day screening period prior to Day 0.\n\n          -  Subjects who wish to enroll in the long-term discontinuation group have voluntarily\n             withdrawn from their continuation studies.\n\n        Exclusion Criteria:\n\n          -  Subjects who have developed clinical evidence of significant, unstable or\n             uncontrolled, acute or chronic diseases not due to SLE, or experienced an adverse\n             event (AE) in their belimumab continuation study that could, in the opinion of the\n             principle investigator, put the subject at undue risk.\n\n          -  Subjects who have developed any other medical diseases, laboratory abnormalities, or\n             conditions that, in the opinion of the principle investigator, makes the subject\n             unsuitable for the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "135", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119156", 
            "org_study_id": "116027"
        }, 
        "intervention": {
            "arm_group_label": [
                "Treatment Holiday Group", 
                "Control Group"
            ], 
            "description": "Monthly intravenous infusions dosed as 10 mg/kg body weight", 
            "intervention_name": "Belimumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "treatment holiday", 
            "PGA", 
            "belimumab", 
            "Lymphostat-B", 
            "rebound", 
            "SELENA SLEDAI", 
            "Systemic Lupus Erythematosus", 
            "immunogenicity"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "275-8580"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060-8604"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Nagasaki", 
                        "country": "Japan", 
                        "zip": "857-1195"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "US GSK Clinical Trials Call Center", 
                    "phone": "877-379-3718"
                }, 
                "contact_backup": {
                    "email": "GSKClinicalSupportHD@gsk.com", 
                    "last_name": "EU GSK Clinical Trials Call Center", 
                    "phone": "+44 (0) 20 8990 4466"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "133-792"
                    }, 
                    "name": "GSK Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "An Open-label, Non-randomized, 52-Week Study to Evaluate Treatment Holidays and Rebound Phenomenon After Treatment With Belimumab 10 mg/kg in Systemic Lupus Erythematosus Subjects.", 
        "overall_contact": {
            "email": "GSKClinicalSupportHD@gsk.com", 
            "last_name": "US GSK Clinical Trials Call Center", 
            "phone": "877-379-3718"
        }, 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Korea: Food and Drug Administration", 
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "China: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Systemic lupus erythematosus disease activity assessment scale", 
                "measure": "SELENA SLEDAI", 
                "safety_issue": "No", 
                "time_frame": "Over 52 weeks"
            }, 
            {
                "description": "Disease assessment scale for lupus flares", 
                "measure": "SLE Flare Index", 
                "safety_issue": "No", 
                "time_frame": "Over 52 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119156"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events", 
            "measure": "Safety", 
            "safety_issue": "No", 
            "time_frame": "Over 52 weeks"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}